New drug combo shows promise for Tough-to-Treat leukemia in younger patients
NCT ID NCT04269213
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a chemotherapy drug called CPX-351 in people under 60 with secondary acute myeloid leukemia (AML), a type of leukemia that develops after other blood disorders or cancer treatments. The goal is to see how well the drug can make the cancer disappear or improve blood counts. About 21 participants will receive the treatment, and researchers will track how long any benefits last.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Allegheny Health Network Cancer Institute - West Penn Hospital
Pittsburgh, Pennsylvania, 15224, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
SUNY Upstate Medical Center
Syracuse, New York, 13210, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a liposomal chemo combo outsmart tough leukemias?
- Can a Platelet-Boosting drug speed recovery for older leukemia patients?
- Radioactive antibody hones in on cancer cells to boost transplant success
- Can a simple blood test predict leukemia risk after cancer therapy?
- Could a targeted drug keep AML in check?